Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression
•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6”...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2022-05, Vol.106, p.108620-108620, Article 108620 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 108620 |
---|---|
container_issue | |
container_start_page | 108620 |
container_title | International immunopharmacology |
container_volume | 106 |
creator | Ashour, Rehab H. Hazem, Noha M. AbdElfattah, Amany A. El-Kady, Rania A. Elmasry, Ahlam |
description | •Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid.
Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair. |
doi_str_mv | 10.1016/j.intimp.2022.108620 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2636142796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576922001047</els_id><sourcerecordid>2636142796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</originalsourceid><addsrcrecordid>eNp9kd2K1TAUhYsozjj6BiIBb7zpMf9JEYTD-DdwwIGj1yFNdzSHtqlJK54n8LVN7eiFF15sEna-tXbYq6qeErwjmMiXp10Y5zBMO4opLS0tKb5XXRKtdE0UFvfLXUhVCyWbi-pRzieMS5-Th9UFE5QrLZrL6uctjHPMdkS3sT_npfd2BnSMXVgGZJcvQ3nOaP4KayU7wTIHh8B7cDOKHol6P4SxGPTBnUuhvQsdCiN6czwiF_swh4yG2EH_6rdLij2suptDzQSCH1OCnEMcH1cPvO0zPLk7r6rP795-uv5QHz6-v7neH2rHsJhri53XLZeddw1I7VvRCsVB-cZapl1nMQfJG9ZSYBJbTBuMGVeKek4Ex5JdVS823ynFbwvk2QwhO-h7O0JcsqGSScKpalb0-T_oKS5pLL8rlNBUN4TpQvGNcinmnMCbKYXBprMh2KxBmZPZgjJrUGYLqsie3Zkv7QDdX9GfZArwegOgbON7gGSyCzA66EIquzddDP-f8AubCKXe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2658289138</pqid></control><display><type>article</type><title>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</title><source>Elsevier ScienceDirect Journals</source><creator>Ashour, Rehab H. ; Hazem, Noha M. ; AbdElfattah, Amany A. ; El-Kady, Rania A. ; Elmasry, Ahlam</creator><creatorcontrib>Ashour, Rehab H. ; Hazem, Noha M. ; AbdElfattah, Amany A. ; El-Kady, Rania A. ; Elmasry, Ahlam</creatorcontrib><description>•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid.
Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2022.108620</identifier><identifier>PMID: 35247859</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cell density ; Colitis ; Colon ; Combined treatment ; Crypts ; Dextran ; Dextran sulfate ; Dextrans ; Drugs ; Enzyme-linked immunosorbent assay ; Gene expression ; Immune response ; Immune system ; Immunohistochemistry ; Immunosuppressive agents ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Interleukin 6 ; Interleukin-35 ; Ki67 ; Mucosa ; Pentosan polysulfate ; Sodium ; Ulcerative colitis</subject><ispartof>International immunopharmacology, 2022-05, Vol.106, p.108620-108620, Article 108620</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV May 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</citedby><cites>FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</cites><orcidid>0000-0001-9744-4609</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576922001047$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35247859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ashour, Rehab H.</creatorcontrib><creatorcontrib>Hazem, Noha M.</creatorcontrib><creatorcontrib>AbdElfattah, Amany A.</creatorcontrib><creatorcontrib>El-Kady, Rania A.</creatorcontrib><creatorcontrib>Elmasry, Ahlam</creatorcontrib><title>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid.
Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.</description><subject>Cell density</subject><subject>Colitis</subject><subject>Colon</subject><subject>Combined treatment</subject><subject>Crypts</subject><subject>Dextran</subject><subject>Dextran sulfate</subject><subject>Dextrans</subject><subject>Drugs</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Gene expression</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunohistochemistry</subject><subject>Immunosuppressive agents</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Interleukin 6</subject><subject>Interleukin-35</subject><subject>Ki67</subject><subject>Mucosa</subject><subject>Pentosan polysulfate</subject><subject>Sodium</subject><subject>Ulcerative colitis</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kd2K1TAUhYsozjj6BiIBb7zpMf9JEYTD-DdwwIGj1yFNdzSHtqlJK54n8LVN7eiFF15sEna-tXbYq6qeErwjmMiXp10Y5zBMO4opLS0tKb5XXRKtdE0UFvfLXUhVCyWbi-pRzieMS5-Th9UFE5QrLZrL6uctjHPMdkS3sT_npfd2BnSMXVgGZJcvQ3nOaP4KayU7wTIHh8B7cDOKHol6P4SxGPTBnUuhvQsdCiN6czwiF_swh4yG2EH_6rdLij2suptDzQSCH1OCnEMcH1cPvO0zPLk7r6rP795-uv5QHz6-v7neH2rHsJhri53XLZeddw1I7VvRCsVB-cZapl1nMQfJG9ZSYBJbTBuMGVeKek4Ex5JdVS823ynFbwvk2QwhO-h7O0JcsqGSScKpalb0-T_oKS5pLL8rlNBUN4TpQvGNcinmnMCbKYXBprMh2KxBmZPZgjJrUGYLqsie3Zkv7QDdX9GfZArwegOgbON7gGSyCzA66EIquzddDP-f8AubCKXe</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Ashour, Rehab H.</creator><creator>Hazem, Noha M.</creator><creator>AbdElfattah, Amany A.</creator><creator>El-Kady, Rania A.</creator><creator>Elmasry, Ahlam</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9744-4609</orcidid></search><sort><creationdate>20220501</creationdate><title>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</title><author>Ashour, Rehab H. ; Hazem, Noha M. ; AbdElfattah, Amany A. ; El-Kady, Rania A. ; Elmasry, Ahlam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cell density</topic><topic>Colitis</topic><topic>Colon</topic><topic>Combined treatment</topic><topic>Crypts</topic><topic>Dextran</topic><topic>Dextran sulfate</topic><topic>Dextrans</topic><topic>Drugs</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Gene expression</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunohistochemistry</topic><topic>Immunosuppressive agents</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Interleukin 6</topic><topic>Interleukin-35</topic><topic>Ki67</topic><topic>Mucosa</topic><topic>Pentosan polysulfate</topic><topic>Sodium</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ashour, Rehab H.</creatorcontrib><creatorcontrib>Hazem, Noha M.</creatorcontrib><creatorcontrib>AbdElfattah, Amany A.</creatorcontrib><creatorcontrib>El-Kady, Rania A.</creatorcontrib><creatorcontrib>Elmasry, Ahlam</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ashour, Rehab H.</au><au>Hazem, Noha M.</au><au>AbdElfattah, Amany A.</au><au>El-Kady, Rania A.</au><au>Elmasry, Ahlam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>106</volume><spage>108620</spage><epage>108620</epage><pages>108620-108620</pages><artnum>108620</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid.
Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35247859</pmid><doi>10.1016/j.intimp.2022.108620</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9744-4609</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-5769 |
ispartof | International immunopharmacology, 2022-05, Vol.106, p.108620-108620, Article 108620 |
issn | 1567-5769 1878-1705 |
language | eng |
recordid | cdi_proquest_miscellaneous_2636142796 |
source | Elsevier ScienceDirect Journals |
subjects | Cell density Colitis Colon Combined treatment Crypts Dextran Dextran sulfate Dextrans Drugs Enzyme-linked immunosorbent assay Gene expression Immune response Immune system Immunohistochemistry Immunosuppressive agents Inflammatory bowel disease Inflammatory bowel diseases Interleukin 6 Interleukin-35 Ki67 Mucosa Pentosan polysulfate Sodium Ulcerative colitis |
title | Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A40%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentosan%20Polysulfate%20Sodium%20augments%20the%20therapeutic%20effect%20of%205-Aminosalicylic%20Acid%20in%20DSS%20colitis%20model;%20the%20role%20of%20IL-35%20expression&rft.jtitle=International%20immunopharmacology&rft.au=Ashour,%20Rehab%20H.&rft.date=2022-05-01&rft.volume=106&rft.spage=108620&rft.epage=108620&rft.pages=108620-108620&rft.artnum=108620&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2022.108620&rft_dat=%3Cproquest_cross%3E2636142796%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2658289138&rft_id=info:pmid/35247859&rft_els_id=S1567576922001047&rfr_iscdi=true |